EP0636175A1 - Fragments de decorine et procede d'inhibition de facteurs de regulation cellulaire - Google Patents

Fragments de decorine et procede d'inhibition de facteurs de regulation cellulaire

Info

Publication number
EP0636175A1
EP0636175A1 EP93909477A EP93909477A EP0636175A1 EP 0636175 A1 EP0636175 A1 EP 0636175A1 EP 93909477 A EP93909477 A EP 93909477A EP 93909477 A EP93909477 A EP 93909477A EP 0636175 A1 EP0636175 A1 EP 0636175A1
Authority
EP
European Patent Office
Prior art keywords
decorin
tgfβ
cell regulatory
protein
regulatory factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93909477A
Other languages
German (de)
English (en)
Inventor
Erkki I. Ruoslahti
Michael D. Pierschbacher
Jose Cardenas
William Craig
Daniel G. Mullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of EP0636175A1 publication Critical patent/EP0636175A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Definitions

  • This invention relates to cell biology and more specifically to the control of cell proliferation by inhibiting cell regulatory factors.
  • proteoglycans are proteins that carry one or more glycosaminoglycan chains.
  • the known proteoglycans carry out a wide variety of functions and are found in a variety of cellular locations.
  • Many proteoglycans are components of extracellular matrix, where they participate in the assembly of cells and effect the attachment of cells to the matrix.
  • Decorin also known as PG-II or PG-40, is a small proteoglycan produced by fibroblasts. Its core protein has a molecular weight of about 40,000 daltons. The core has been sequenced (Krusius and Ruoslahti, Proc. Natl. Acad.
  • TGF ⁇ Transforming growth factor ⁇ 's
  • TGF ⁇ Transforming growth factor ⁇ 's
  • Five different TGF ⁇ 's are known, but the functions of only two, TGF ⁇ -1 and TGF ⁇ -2, have been characterized in any detail.
  • TGF ⁇ 's are the subject of U.S. Patent Nos. 4,863,899; 4,816,561; and 4,742,003 which are incorporated by reference.
  • TGF ⁇ -1 and TGF ⁇ -2 are publicly available through many commercial sources (e.g. R & D Systems, Inc., Minneapolis, MN) .
  • TGF ⁇ binds to cell surface receptors possessed by essentially all types of cells, causing profound changes in them. In some cells, TGF ⁇ promotes cell proliferation, in others it suppresses proliferation. A marked effect of TGF ⁇ is that it promotes the production of extracellular matrix proteins and their receptors by cells (for review see Keski-Oja et al., J. Cell Biochem 33:95 (1987); Massague, Cell 49:437 (1987); Roberts and Sporn in "Peptides Growth Factors and Their Receptors” (Springer-Verlag, Heidelberg (1989)).
  • TGF ⁇ has many essential cell regulatory functions, improper TGF ⁇ activity can be detrimental to an organism. Since the growth of mesenchyme and proliferation of mesenchymal cells is stimulated by TGF ⁇ , some tumor cells may use TGF ⁇ as an autocrine growth factor. Therefore, if the growth factor activity of TGF ⁇ could be prevented, tumor growth could be controlled. In other cases the inhibition of cell proliferation by TGF ⁇ may be detrimental, in that it may prevent healing of injured tissues. The stimulation of extracellular matrix production by TGF ⁇ is important in situations such as wound healing. However, in some cases the body takes this response too far and an excessive accumulation of extracellular matrix ensues. An example of excessive accumulation of extracellular matrix is glomerulonephritis, a disease with a detrimental involvement of TGF ⁇ .
  • the present invention provides active fragments of proteins having a cell regulatory factor binding domain.
  • the invention further provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises a cell regulatory factor binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids.
  • the present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, and more specifically to active fragments of decorin or a functional equivalent of decorin to bind TGF ⁇ or other cell regulatory factors.
  • the invention also provides a novel cell regulatory factor designated Morphology Restoring Factor, (MRF) . Also provided are methods of identifying, detecting and purifying cell regulatory factors and proteins that bind and affect the activity of cell regulatory factors.
  • MRF Morphology Restoring Factor
  • Figure 1 shows expression of decorin cDNA containing a mutation of the serine acceptor site to alanine.
  • COS-l cultures were transfected with cDNA coding for wild-type decorin (lane 1) , decorin in which the serine-4 residue was replaced by an alanine (lane 2) , or decorin in which the serine-4 residue was replaced by a threonine (lane 3) .
  • Immunoprecipitations were performed with an anti-decorin antibody and medium which was labeled with 3S S-sulfate (A) or 3 H-leucine (B) .
  • Lane 4 shows an immunoprecipitate from mock transfected COS-l cultures. Arrow indicates top of gel. The numbers indicate M r X 10" 3 for molecular weight standards.
  • Figure 2 shows binding of [ 125 I]TGF,31 to decorin-
  • Sepharose (A) Fractionation of [ 125 I]-TGF31 by decorin- Sepharose affinity chromatography. [ 125 I]TGF31 (5 x 10 s cpm) was incubated in BSA-coated polypropylene tubes with 0.2 ml of packed decorin-Sepharose ( ⁇ ) or gelatin-Sepharose (o) in 2 ml of PBS pH 7.4, containing 1 M NaCl and 0.05% Tween 20. After overnight incubation, the affinity matrices were transferred into BSA-coated disposable columns (Bio Rad) and washed with the binding buffer.
  • Figure 3 shows the inhibition of binding of [ 125 I]TGF31 to decorin by proteoglycans and their core proteins:
  • A Competition of [ 125 I]TGF31 binding to decorin- coated microtiter wells by recombinant decorin ( ⁇ ) , decorin isolated from bovine skin (PGII) (I), biglycan isolated from bovine articular cartilage (PGI) ( A ), chicken cartilage proteoglycan (o) , and BSA (D) .
  • ⁇ decorin isolated from bovine skin
  • PGII decorin isolated from bovine skin
  • PGI biglycan isolated from bovine articular cartilage
  • o bovine articular cartilage
  • BSA BSA
  • Each point represents the mean of duplicate determinants.
  • B Competition of [ 125 I]TGF31 binding with chondroitinase ABC- treated proteoglycans and BSA. The concentrations of competitors were expressed as intact proteoglycan.
  • the symbols are the same as
  • FIG. 4 shows neutralization of the growth regulating activity of TGF31 by decorin:
  • A Shows inhibition of TGF31-induced proliferation of CHO cells by decorin.
  • [ 3 H]Thymidine incorporation assay was performed in the presence of 5 ng/ml of TGF/3-1 and the indicated concentrations of purified decorin ( ⁇ ) or BSA (o). At the concentration used, TGF/3-1 induced a 50% increase of [ 3 H]thymidine incorporation in the CHO cells.
  • Each point shows the mean ⁇ standard deviation of triplicate samples.
  • (B) Shows neutralization of TGF/31-induced growth inhibition in MvlLu cells by decorin.
  • the assay was performed as in A except that TGF/3-1 was added at 0.5 ng/ml. This concentration of TGF3-1 induces 50% reduction of [ 3 H]thymidine incorporation in the MvlLu cells.
  • Figure 5A shows separation of growth inhibitory activity from decorin-expressing CHO cells by gel filtration. Serum-free conditioned medium of decorin overexpressor cells was fractionated by DEAE-Sepharose chromatography in a neutral Tris-HCl buffer and fractions containing growth inhibitory activity were pooled, made 4M with guanidine-HCl and fractionated on a Sepharose CL-6B column equilibrated with the same guanidine-HCl solution.
  • BSA bovine serum albumin (Mr ⁇ -66,000)
  • Cy cytochrome c (Mr * ⁇ 12,400); Ap:aprotinin
  • Figure 5B shows identification of the growth stimulatory material from gel filtration as TGF/31.
  • the growth stimulatory activity from the late fractions from Sepharose 6B (bar in panel A) was identified by inhibiting the activity with protein A-purified IgG from an anti-TGF/3 antiserum.
  • Data represent percent inhibition of growth stimulatory activity in a [ 3 H]thymidine incorporation assay. Each point shows the mean ⁇ standard deviation of triplicate determinations.
  • Anti-TGF/31 (•), normal rabbit IgG (o) .
  • FIG. 6 is a schematic diagram of MBP-decorin fragment fusion proteins.
  • LRR is a leucine rich repeat.
  • MBP is maltose binding protein.
  • Figure 7 shows the results of binding studies of 125 I-TGF ⁇ to immobilized recombinant decorin (DC13) and MBP- decorin fragments PT-65, PT-71, PT-72 and PT-73.
  • Figure 8 shows the results of binding studies of 125 I-TGF ⁇ to immobilized decorin (DC-18v) and MBP-decorin fragments PT-71, PT-72, PT-84, PT-85, PT-86 and PT-87.
  • FIG. 10 shows the results of binding studies of 125 I-TGF ⁇ to L-M(tk-) cells in the presence of decorin and decorin fragments PT-71, PT-72, PT-84 and PT-85.
  • Figure 11 shows the results of binding studies of 125 ⁇ -TGF ⁇ l to L-M(tk-) cells in the presence of decorin and recombinant decorin fragments PT-71, PT-72, PT-86 and PT- 87.
  • Figure 12 shows the results of binding studies of 125 I-TGF ⁇ l to L-M(tk-) cells in the presence of synthetic decorin peptide fragments P 25 -Q 36 , H 31 -S 37 and H 31 -L 42 and a control peptide corresponding to the N-terminal 15-mer.
  • Figure 13 shows the results of 125 I-TGF- ⁇ binding to immobilized decorin with or without the presence of synthetic decorin peptide fragments 16D, 16E, 16G and 16H as well as a control peptide corresponding to the N- terminal 15-mer.
  • the invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises the cell regulatory factor binding domain of a protein.
  • the protein can be characterized by a leucine-rich repeat of about 24 amino acids. Since diseases such as cancer result from uncontrolled cell proliferation, the invention can be used to treat such diseases.
  • cell regulatory factor is meant a molecule which can regulate an activity of a cell.
  • the cell regulatory factors are generally proteins which bind cell surface receptors and include growth factors.
  • Examples of cell regulatory factors include the five TGF ⁇ ' ⁇ , platelet- derived growth factor (PDGF) , epidermal growth factor, insulin like growth factor I and II, fibroblast growth factor, interleukin-2 , nerve growth factor, hemopoietic cell growth factors (IL-3, GM-CSF, M-CSF, G-CSF, erythropoietin) and the newly discovered Morphology Restoring Factor, hereinafter "MRF".
  • PDGF platelet- derived growth factor
  • epidermal growth factor insulin like growth factor I and II
  • fibroblast growth factor interleukin-2
  • nerve growth factor IL-3, GM-CSF, M-CSF, G-CSF, erythropoietin
  • MRF Morphology Restoring Factor
  • Different regulatory factors can be bound by different proteins which can affect
  • cell regulatory factor binding domain a fragment of a protein which binds to the cell regulatory factor.
  • a protein fragment that retains the binding activity is included within the scope of the invention and is referred to herein as an active fragment. Fragments that retain such activity, such as active fragments of decorin or biglycan, can be recognized by their ability to competitively inhibit the binding of, for example, decorin to TGF ⁇ , or of other polypeptides to their cognate growth factors.
  • Active fragments can be obtained by proteolytic digestion of the native polypeptide according to methods known in the art pr as described, for example, in Example VIII.
  • active fragments can be synthesized based on the known amino acid sequence by methods known to those skilled in the art or as described in Example VIII.
  • the fragments can also be produced recombinantly by methods known in the art or as described in Example V. Examples of active fragments are included in Tables 4-15.
  • decorin can be attached to an affinity matrix, as by the method of Example II. Labelled TGF ⁇ and an active fragment can then be contacted with the affinity matrix and the amount of TGF ⁇ bound thereto determined.
  • decorin refers to a proteoglycan having substantially the structural characteristics attributed to it in Krusius and Ruoslahti, supra . Human fibroblast decorin has substantially the amino acid sequence presented in Krusius and Ruoslahti, supra .
  • “Decorin” refers both to the native composition and to modifications thereof which substantially retain the functional characteristics.
  • Decorin core protein refers to decorin that no longer is substantially substituted with glycosaminoglycan and is included in the definition of decorin.
  • Decorin can be rendered glycosaminoglycan-free by mutation or other means, such as by producing recombinant decorin in cells incapable of attaching glycosaminoglycan chains to a core protein.
  • Functional equivalents of decorin include modifications of decorin that retain its functional characteristics and molecules that are homologous to decorin, such as the decorin family members biglycan and fibromodulin, for example, that have the similar functional activity of decorin. Modifications can include, for example, the addition of one or more side chains that do not interfere with tne functional activity of the decorin core protein.
  • the regulatory factor binding proteins each contain leucine-rich repeats of about 24 amino acids which can constitute 80% of the protein, it is likely that the fragments which retain the binding activity occur in the leucine-rich repeats. However, it is possible the binding activity resides elsewhere such as in the carboxy terminal amino acids or the junction of the repeats and the carboxy terminal amino acids.
  • the invention teaches a general method whereby one skilled in the art can identify proteins that can bind to cell regulatory factors or identify cell regulatory factors that bind to a certain family of proteins.
  • the invention also teaches a general method in which these novel proteins or known existing proteins can be assayed to determine if they affect an activity of a cell regulatory factor.
  • the invention teaches the discovery that decorin and biglycan bind TGF ⁇ -1 and MRF and that such binding can inhibit the cell regulatory functions of TGF ⁇ - 1.
  • both decorin and biglycan are about 80% homologous and contain a leucine-rich repeat of about 24 amino acids in which the arrangement of the leucine residues is conserved. As defined, each repeat generally contains at least two leucine residues and can contain five or more.
  • proteoglycans are thus considered members of the same protein family. See Ruoslahti, supra, Fisher et al., J. Biol. Chem., 264:4571-4576 (1989) and Patthy, J. Mol. Biol., 198:567-577 (1987), all of which are incorporated by reference.
  • Other known or later discovered proteins having this leucine-rich repeat, i.e., fibromodulin would be expected to have a similar cell regulatory activity. The ability of such proteins to bind cell regulatory factors could easily be tested, for example by affinity chromatography or microtiter assay as set forth in Example II, using known cell regulatory factors, such as TGF ⁇ -1.
  • any later discovered cell regulatory factor could be tested, for example by affinity chromatography using one or more regulatory factor binding proteins. Once it is determined that such binding occurs, the effect of the binding on the activity of all regulatory factors can be determined by methods such as growth assays as set forth in Example III. Moreover, one skilled in the art could simply substitute a novel cell regulatory factor for TGF ⁇ -1 or a novel leucine-rich repeat protein for decorin or biglycan in the Examples to determine their activities. Thus, the invention provides general methods to identify and test novel cell regulatory factors and proteins which affect the activity of these factors.
  • the invention also provides a novel purified compound comprising a cell regulatory factor attached to a purified polypeptide wherein the polypeptide comprises the cell regulatory factor binding domain of a protein and the protein is characterized by a leucine-rich repeat of about 24 amino acids.
  • the invention further provides a novel purified protein, designated MRF, having a molecular weight of about 20 kd, which can be isolated from CHO cells, copurifies with decorin under nondissociating conditions, separates from decorin under dissociating conditions, changes the morphology of transformed 3T3 cells, and has an activity which is not inhibited with anti-TGF ⁇ -1 antibody. Additionally, MRF separates from TGF ⁇ -1 in HPLC.
  • the invention still further provides a method of purifying a cell regulatory factor comprising contacting the regulatory factor with a protein which binds the cell regulatory factor and has a leucine-rich repeat of about 24 amino acids and to purify the regulatory factor which becomes bound to the protein.
  • the method can be used, for example, to purify TGF ⁇ -1 by using decorin.
  • the invention additionally provides a method of treating a pathology caused by a TGF ⁇ -regulated activity comprising contacting the TGF ⁇ with a purified polypeptide, wherein the polypeptide comprises the TGF ⁇ binding domain of a protein and wherein the protein is characterized by a leucine-rich repeat of about 24 amino acids, whereby the pathology-causing activity is prevented or reduced.
  • a pathology caused by a TGF ⁇ -regulated activity
  • the method is generally applicable, specific examples of pathologies which can be treated include a cancer, a fibrotic disease, and glomerulonephritis.
  • decorin can be used to bind TGF ⁇ -1, destroying TGF ⁇ -l's growth stimulating activity on the cancer cell.
  • a method of preventing the inhibition of a cell regulatory factor is provided.
  • the method comprises contacting a protein which inhibits an activity of a cell regulator factor with a molecule which inhibits the activity of the protein.
  • a protein which inhibits an activity of a cell regulator factor with a molecule which inhibits the activity of the protein.
  • decorin could be bound by a molecule, such as an antibody, which prevents decorin from binding TGF ⁇ -1, thus preventing decorin from inhibiting the TGF ⁇ -1 activity.
  • the TGF ⁇ -1 wound healing activity could be promoted by binding TGF ⁇ -1 inhibitors.
  • the mammalian expression vectors pSV2-decorin and pSV2-decorin/CP-thr4 core protein were constructed by ligating the decorin cDNA or the mutagenized decorin cDNA into 3.4 kb HindiII-Bam HI fragment of pSV2 (Mulligan and Berg, Science 209:1423 (1980), which is incorporated herein by reference) .
  • Dihydrofolate reductase (dhfr)-negative CHO cells (CHO-DG44) were cotransfected with pSV2-decorin or pSV2- decorin/CP and pSV2dhfr by the calcium phosphate coprecipitation method.
  • the CHO-DG44 cells transfected with pSV2-decorin are deposited with the American Type Culture Collection under Accession Number ATCC No. CRL 10332.
  • the transfected cells were cultured in nucleoside- minus alpha-modified minimal essential medium ( ⁇ -MEM) , (GIBCO, Long Island) supplemented with 9% dialyzed fetal calf serum, 2 mM glutamine, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin. Colonies arising from transfected cells were picked using cloning cylinders, expanded and checked for the expression of decorin by immunoprecipitation from 35 S0 4 -labeled culture supernatants. Clones expressing a substantial amount of decorin were then subjected to gene amplification by stepwise increasing concentration of methotrexate (MTX) up to 0.64 ⁇ M (Kaufman and Sharp, J. Mol.
  • MTX methotrexate
  • the core protein was expressed in
  • COS-l cells as described in Adams and Rose, Cell 41:1007, (1985), which is incorporated herein by reference. Briefly, 6-well multiwell plates were seeded with 3-5xl0 5 cells per 9.6 cm 2 growth area and allowed to attach and grow for 24 hours. Cultures were transfected with plasmid DNA when they were 50-70% confluent. Cell layers were washed briefly with Tris buffered saline (TBS) containing 50 mM Tris, 150 mM NaCl pH 7.2, supplemented with 1 mM CaCl 2 and 0.5 mM MgCl 2 at 37°C to prevent detachment.
  • TBS Tris buffered saline
  • the wells were incubated for 30 minutes at 37°C with 1 ml of the above solution containing 2 ⁇ g of closed circular plasmid DNA and 0.5 mg/ml DEAE-Dextran (Sigma) of average molecular mass of 500,000.
  • cultures were transfected with the pSV2 expression plasmid lacking any decorin insert or mock transfected with no DNA.
  • Culture were then incubated for 3 hours at 37°C with Dulbecco's Modified Eagle's medium (Irvine Scientific) containing 10% fetal calf serum and 100 ⁇ M chloroquine (Sigma) , after removing the DNA/TBS/DEAE- Dextran solution and rinsing the wells with TBS.
  • the cell layers were then rinsed twice and cultured in the above medium, lacking any chloroquine, for approximately 36 hours.
  • WI38 human embryonic lung fibroblasts were routinely cultured in the same medium.
  • COS-l cultures were radiolabeled 36-48 hours after transfection with the plasmid DNAs. All radiolabeled metabolic precursors were purchased from New England Nuclear (Boston, MA) . The isotopes used were 35 S-sulfate (460 mCi/ml), L-[3,4,5- 3 H(N) ] -leucine (140 Ci/ml) and L- [ 14 C(U)] - amino acid mixture (product number 445E) .
  • Cultures were labeled for 24 hours in Ham's F-12 medium (GIBCO Labs), supplemented with 10% dialyzed fetal calf serum, 2 mM glutamine and 1 mM pyruvic acid, and containing 200 ⁇ Ci/ml 35 S-sulfate or 3 H-leucine, or 10 ⁇ Ci/ml of the 14 C-amino acid mixture.
  • the medium was collected, supplemented with 5 mM EDTA, 0.5 mM phenylmethylsulfonylfluoride, 0.04 mg/ml aprotinin and 1 ⁇ g/ml pepstatin to inhibit protease activity, freed of cellular debris by centrifugation for 20 minutes at 2,000 x G and stored at -20°C.
  • Cell extracts were prepared by rinsing the cell layers with TBS and then scraping with a rubber policeman into 1 ml/well of ice cold cell lysis buffer: 0.05 M Tris-HCl, 0.5 M NaCl, 0.1% BSA, 1% NP-40, 0.5% Triton X-100, 0.1% SDS, pH 8.3. The cell extracts were clarified by.centrifugation for 1.5 hours at 13,000 x G at 4°C.
  • Rabbit antiserum was prepared against a synthetic peptide based on the first 15 residues of the mature form of the human decorin core protein (Asp-Glu-Ala-Ser-Gly-Ile- Gly-Pro-Glu-Val-Pro-Asp-Asp-Arg-Asp) .
  • the synthetic peptide and the antiserum against it have been described elsewhere (Krusius and Ruoslahti, 1986 supra . ) Briefly, the peptide was synthesized with a solid phase peptide synthesizer (Applied Biosystems, Foster City, CA) by using the chemistry suggested by the manufacturer.
  • the peptide was coupled to keyhole limpet hemocyanin by using N- succinimidyl 3-(2-pyridyldithio) propionate (Pharmacia Fine Chemicals, Piscataway, NJ) according to the manufacturer's instructions.
  • the resulting conjugates were emulsified in Freund's complete adjuvant and injected into rabbits. Further injections of conjugate in Freund's incomplete adjuvant were given after one, two and three months. The dose of each injection was equivalent to 0.6 mg of peptide. Blood was collected 10 days after the third and fourth injection.
  • the antisera were tested against the glutaraldehyde-cross linked peptides and isolated decorin in ELISA (Engvall, Meth. Enzymol. 70:419-439 (1980)), in immunoprecipitation and immunoblotting, and by staining cells in immunofluorescence, as is well known in the art.
  • Immunoprecipitations were performed by adding 20 ⁇ l of antiserum to the conditioned medium or cell extract collected from duplicate wells and then mixing overnight at 4°C. Immunocomplexes were isolated by incubations for 2 hours at 4°C with 20 ⁇ l of packed Protein A-agarose (Sigma) . The beads were washed with the cell lysis buffer, with three tube changes, and then washed twice with phosphate-buffered saline prior to boiling in gel electrophoresis sample buffer containing 10% mercaptoethanol. Immunoprecipitated proteins were separated by SDS-PAGE in 7.5-20% gradient gels or 7.5% non- gradient gels as is well known in the art.
  • Fluorography was performed by using Enlightning (New England Nuclear) with intensification screens. Typical exposure times were for 7-10 days at -70°C. Autoradiographs were scanned with an LKB Ultroscan XL Enhanced Laser Densitometer to compare the relative intensities and mobilities of the proteoglycan bands.
  • FIG. 1 shows the expression of decorin (lanes 1) and its threonine-4 (lanes 3) and alanine-4 (lanes 2) mutated core proteins expressed in COS cell transfectants.
  • 35 S0 4 -labeled (A) and 3 H-leucine labeled (B) culture supernatants were immunoprecipitated with rabbit antipeptide antiserum prepared against the NH 2 - terminus of human decorin.
  • Decorin concentration was determined by competitive ELISA as described in Yamaguchi and Ruoslahti, supra .
  • the fractions containing decorin were pooled and further fractionated on a Sephadex gel filtration column equilibrated with 8 M urea in the Tris- HC1 buffer. Fractions containing decorin were collected.
  • the core protein is purified from cloned cell lines transfected with the pSV2-decorin/CP vector or the vector containing the alanine-mutated cDNA and amplified as described above. These cells are grown to confluency as described above. At confluency the cell monolayer is washed four times with serum-free medium and incubated in ⁇ MEM supplemented with 2 mM glutamine for 2 hours. This spent medium is discarded.
  • the slurry is poured into a column, washed extensively with the preequilibration buffer and eluted with 0.1M - 1M linear gradient of NaCl in 50 mM Tris/HCl, pH 7.4.
  • the fractions containing decorin are pooled, dialyzed against 50 mM NH 4 HC0 3 and lyophilized.
  • the lyophilized material is dissolved in 50 mM Tris, pH 7.4, containing 8M urea and applied to a Sephacryl S-200 column (1.5 X 110 cm). Fractions containing decorin core proteins as revealed by SDS-polyacrylamide electrophoresis are collected and represent purified decorin core protein.
  • TGF ⁇ -1 (Calbiochem, La Jolla, CA) was 125 I-labelled by the chloramine T method (Frolik et al., J. Biol. Chem. 259:10995-11000 (1984)) which is incorporated herein by reference and the labeled TGF ⁇ was separated from the unreacted iodine by gel filtration on Sephadex G-25, equilibrated with phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) ( Figure 2).
  • PBS phosphate buffered saline
  • BSA bovine serum albumin
  • [ 125 I]-TGF/31 (5 x 10 5 cpm) was incubated in BSA-coated polypropylene tubes with 0.2 ml of packed decorin-Sepharose (•) or gelatin-Sepharose (o) in 2 ml of PBS pH 7.4, containing 1 M NaCl and 0.05% Tweer. 20. After overnight incubation, the affinity matrices were transferred into BSA-coated disposable columns (Bio Rad) and washed with the binding buffer. Elution was effected first with 3 M NaCl in the binding buffer and then with 8 M urea in the same buffer. Fractions were collected, counted for radioactivity in a gamma counter and analyzed by SDS-PAGE under nonreducing condition using 12% gels.
  • FIG 2A shows the radioactivity profile from the two columns and the SDS-PAGE analysis of the fractions is shown in Figure 2B.
  • the TGF ⁇ -1 starting material contains a major band at 25 kd. This band represents the native TGF ⁇ -1 dimer. In addition, there are numerous minor bands in the preparation. About 20-30% of the radioactivity binds to the decorin column and elutes with 8 M urea, whereas only about 2% of the radioactivity is present in the urea-eluted fraction in the control fractionation performed on gelatin-Sepharose ( Figure 2A) .
  • the decorin-Sepharose nonbound fraction contains all of the minor components and some of the 25 kd TGF ⁇ -1, whereas the bound, urea-eluted fraction contains only TGF ⁇ -1 ( Figure 2B) .
  • TGF ⁇ -1 binds specifically to decorin, since among the various components present in the original TGF ⁇ -1 preparation, only TGF ⁇ -1 bound to the decorin-Sepharose affinity matrix and since there was very little binding to the control gelatin-Sepharose affinity matrix.
  • the TGF ⁇ -1 that did not bind to the decorin- Sepharose column may have been denatured by the iodination. Evidence for this possibility was provided by affinity chromatography of unlabeled TGF ⁇ -1 as described below.
  • TGF ⁇ -1 (180 ng) was incubated with decorin- Sepharose or BSA-agarose (0.2 ml packed volume) in PBS (pH 7.4) containing 1% BSA. After overnight incubation at 4°C, the resins were washed with 15 ml of the buffer and eluted first with 5 ml of 3 M NaCl in PBS then with 5 ml of PBS containing 8 M urea. Aliquots of each pool were dialyzed against culture medium without serum and assayed for the inhibition of [ 3 H]thymidine incorporation in MvlLu cells (Example III).
  • TGF ⁇ -1 The amounts of TGF ⁇ -1 in each pool were calculated from the standard curve of [ 3 H]thymidine incorporation obtained from a parallel experiment with known concentration of TGF ⁇ -1. The results show that the TGF ⁇ -1 bound essentially quantitatively to the decorin column, whereas there was little binding to the control column (Table 1). The partial recovery of the TGF ⁇ -1 activity may be due to loss of TGF ⁇ -1 in the dialyses.
  • TGF ⁇ -1 (ng) Elution Decorin-Sepharose BSA-Sepharose
  • TGF ⁇ -1 The binding of TGF ⁇ -1 to decorin was also examined in a microtiter binding assay.
  • the wells of a 96-well microtiter plate were coated overnight with 2 ⁇ g/ml of recombinant decorin in 0.1 M sodium carbonate buffer, pH 9.5.
  • the wells were washed with PBS containing 0.05% Tween (PBS/Tween) and samples containing 5 x 10" cpm of [ 125 IJ-TGF ⁇ -l and various concentrations of competitors in PBS/Tween were added to each well.
  • PBS/Tween PBS containing 0.05% Tween
  • proteoglycans were digested with chondroitinase ABC (Seikagaku, Tokyo, Japan) by incubating 500 ⁇ g of proteoglycan with 0.8 units of chondroitinase ABC in 250 ⁇ l of 0.1 M Tris/Cl, pH 8.0, 30 mM sodium acetate, 2 mM PMSF, 10 mM N-ethylmalelmide, 10 mM EDTA, and 0.36 mM pepstatin for 1 hour at 37°C.
  • Recombinant decorin and decorin isolated from bovine skin (PGII) inhibited the binding of [ 125 I]-TGF ⁇ -l, as expected ( Figure 3A) .
  • Bovine serum albumin treated with chondroitinase ABC did not shown any inhibition. Additional binding experiments showed that [ 125 I]-TGF ⁇ -l bound to microtiter wells coated with biglycan or its chondroitinase-treated core protein. These results show that TGF ⁇ -1 binds to the core protein of decorin and biglycan and implicates the leucine-rich repeats these proteins share as the potential binding sites.
  • TGF ⁇ -1 was added to the CHO cell cultures at 5 ng/ml. At this concentration, it induced a 50% increase of [ 3 H3thymidine incorporation in these cells.
  • Serum-free conditioned medium of decorin overexpressor CHO-DG44 cells transfected with decorin cDNA was fractionated by DEAE-Sepharose chromatography in a neutral Tris-HCl buffer and fractions containing growth inhibitory activity dialyzed against 50 mM NH 4 HC0 3 , lyophilized and dissolved in 4 M with guanidine- HCl in a sodium acetate buffer, pH 5.9.
  • the dissolved material was fractionated on a 1.5 x 70 cm Sepharose CL-6B column equilibrated with the same guanidine-HCl solution. The fractions were analyzed by SDS-PAGE, decorin ELISA and cell growth assays, all described above. Three protein peaks were obtained.
  • BSA bovine serum albumin
  • CA carbonic anhydrase
  • Cy cytochrome c
  • AP aprotinin
  • the nature of the growth regulatory activity detected in the low molecular weight fraction was examined with an anti-TGF ⁇ -1 antiserum.
  • the antiserum was prepared against a synthetic peptide from residues 78-109 of the human mature TGF ⁇ -1.
  • Antisera raised by others against a cyclic form of the same peptide, the terminal cysteine residues of which were disulfide-linked, have previously been shown to inhibit the binding of TGF ⁇ -1 to its receptors (Flanders et al.. Biochemistry 27:739-746 (1988), incorporated by reference herein) .
  • the peptide was synthesized in an Applied Biosystems solid phase peptide synthesizer and purified by HPLC.
  • a rabbit was immunized subcutaneously with 2 mg per injection of the peptide which was mixed with 0.5 mg of methylated BSA (Sigma, St. Louis, MO) and emulsified in Freund's complete adjuvant. The injections were generally given four weeks apart and the rabbit was bled approximately one week after the second and every successive injection.
  • the antisera used in this work has a titer (50% binding) of 1:6,000 in radioimmunoassay, bound to TGF ⁇ -1 in immunoblots.
  • This antiserum was capable of inhibiting the activity of purified TGF ⁇ -1 on the CHO cells. Moreover, as shown in Figure 5, the antiserum also inhibited the growth stimulatory activity of the low molecular weight fraction as determined by the [ 3 H3-thymidine incorporation assay on the CHO cells. Increasing concentrations of an IgG fraction prepared from the anti-TGF ⁇ -1 antiserum suppressed the stimulatory effect of the low molecular weight fraction in a concentration-dependent manner (•) . IgG from a normal rabbit serum had no effect in the assay (o) .
  • TGF ⁇ -1 the stimulatory factor in the low molecular weight fraction as TGF ⁇ -1.
  • TGF ⁇ -1 is not the only active compound in that fraction.
  • the cells treated with the low molecular weight fraction were morphologically different from the cells treated with the control IgG or cells treated with antibody alone. This effect was particularly clear when the antibody-treated, low molecular weight fraction was added to cultures of H- ras transformed NIH 3T3 cells (Der et al., Proc. Natl. Acad. Sci. USA 79:3637-3640 (1982)). Cells treated with the low molecular weight fraction and antibody appeared more spread and contact inhibited than the control cells. This result shows that the CHO cell-derived recombinant decorin is associated with a cell regulatory factor, MRF, distinct from the well characterized TGF ⁇ 's.
  • MRF cell regulatory factor
  • MBP-Decorin fragment fusion proteins of varying lengths were engineered such that the Maltose Binding Protein (MBP) was attached to the amino terminus of the gene encoding mature decorin as shown in Figure 6.
  • MBP Maltose Binding Protein
  • the techniques incorporated for such construction are described in F. M. Ausubel et al.. Current Protocols in Molecular Biology, John Wiley and Sons (1987) and Maniatis et al.. Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory (1982), which are incorporated herein by reference.
  • the decorin-encoding DNA fragments were generated by polymerase chain reaction (PCR) , Scharf et al.. Science 233:1076-1078 (1986), which is incorporated herein by reference.
  • the primers synthetic oligonucleotides obtained from Genosys (Houston, Texas), incorporate an Eco RI restriction site at the 5' end and an Xba I restriction site at the 3' end of the PCR product. In some instances, the primers also included a base change to code for a different amino acid.
  • the primers used to generate specific inserts are identified in Table 2, while the primer sequences are identified in Table 3.
  • the template DNA was a large scale CsCl prep of pPG-40 described in Krusius and Ruoslahti, Proc. Natl . Acad. Sci . USA 83 : 7683- 7687 (1986), incorporated herein by reference.
  • the DNA amplification reaction was done in a thermal cycler according to manufacturer's recommendations (Perkin-Elmer Cetus; Norwalk, Conneticut) using the VentTM DNA Polymerase (New England Biolabs; Beverly, Massachussets) .
  • the decorin-encoding DNA fragments cycled 35-40 times at 94°, 40°, and 72°C.
  • PCR products were analyzed by agarose gel electrophoresis, Ausubel et al., supra, and Maniatis et al., supra, to identify and determine the decorin-encoding DNA fragments (see Table 2 under "Insert Size”).
  • the PCR products less than 200 base pairs (bp) in size were purified by electrophoresis onto DEAE-cellulose paper,
  • the decorin-encoding DNA fragments were ligated between the Eco RI and Xba I restriction sites of the polylinker in the vector pMAL-p (Protein Fusion and
  • the ligation had a total of 500 ng of DNA and the molar ratio of insert:vector was 3:1.
  • the ligations were then transformed into Escherichia coli (E. coli ) DH5 ⁇ cells (Gibco BRL; Gaithersburg, Maryland), genotype: F" 80d!acZ ⁇ Ml5, ⁇ (lacZYA-argrF)U169, eoR, recAl, e ⁇ dAl, ⁇ sdRl7(r ⁇ _ , m ⁇ + ) , supE44 ⁇ "' thi-1 , gyrA96, relAl, or E.
  • coli DH5 ⁇ strain provides ⁇ -complementation of the ⁇ - galactosidase gene from pMAL-p. Colonies containing pMAL-p with the decorin-encoding DNA fragments were colorless on plates containing 5-Bromo-4-chloro-3-indolyl-3-D- galactoside (X-gal) due to the interruption of the ⁇ - galatosidase gene. Host cells containing pMAL-p only produces blue colonies.
  • Test expression of MBP-Decorin fragment fusion proteins were performed in the host bacterial strain (see Table 2).
  • An overnight culture of E. coli DH5 ⁇ or E. coli SureTM cells containing the MBP-decorin fragment fusion protein plasmids were made by taking a stab of a frozen stock and inoculating L-Broth, Ausubel et al. , supra , containing 100 ⁇ g/ml ampicillin at 37°C with rapid shaking. The following morning, 1 ml was used to inoculate 10 ml of prewarmed medium (L-Broth containing ampicillin) .
  • the blot was developed, Ausubel et al., supra, with Rabbit anti-PG40 serum (Telios Pharmaceuticals, Inc.; La Jolla, California) to test for PT-65, -73, -74, -75, -76, -77, and -78, and Rabbit anti- MBP serum (made in-house) to test for PT-72, -84, -85, -86, and -87. The results are indicated in Table 2 under "MW.”
  • Production batches of the fusion proteins were prepared as follows. An overnight culture of E. coli DH5 ⁇ cells containing the MBP-Decorin fragment fusion protein plasmids was made by taking a stab of the frozen stock and inoculating L-Broth containing 100 ⁇ g/ml ampicillin at 37°C with rapid shaking. From this culture, 5 ml were used to inoculate a larger 50 ml overnight culture. The following morning, 50 ml of the larger culture were added to 500 ml of pre-warmed media. Typically 1-4 liters were prepared for each batch. After 1 hour at 37°C, 5 ml of 0.1 M IPTG were added per flask and the induced cultures were allowed to incubate for an additional 2-3 hours.
  • the cells were harvested by centrifugation at 5,000 rpm for 10 minutes at 10°C using either a GSA or GS-3 rotor in an RC5B centrifuge (DuPont Instruments; Wilmington, Delaware) .
  • the pellets were resuspended in 0.1 volume of lysis buffer (50 mM Tris- HCl, pH 7.4, 150 mM NaCl, 0.1 M PMSF, and 0.25 mg/ml lysozyme) and incubated for 10-15 minutes on ice.
  • the suspension was freeze/thawed three times by repeated cycling through a dry ice/ethanol bath and a room temperature shaking water bath. The suspension was sheared by homogenization using a dounce homogenizer.
  • the lysate was pre-cleared by centrifugation at 12,000 rpm for 30 minutes in a SA-600 rotor (DuPont) .
  • the cleared supernatant was decanted and saved.
  • a final clarification step was done by centrifuging for 30 minutes at 4°C in an RC-80 ultracentrifuge using an AH-629 rotor (DuPont) .
  • the final cleared lysates were stored either at 4°C or -20°C until ready to be purified.
  • MBP-Decorin fusion proteins were done using an amylose resin (New England Biolabs). Briefly, six to seven ml of resin were packed into a 2.5 x 10 cm glass column in MBP column buffer (10 mM Tris-HCl, pH 8.4, 1 mM EDTA, 0.5 M NaCl). The resin was pre-equilibrated with at least 3 column volumes of MBP column buffer containing 0.25% Tween 20. Cleared lysate as prepared above was diluted 1 part lysate to 1 part 2X MBP column buffer containing 0.5% Tween 20 and added to the column at a flow rate of 50-100 ml/ hr.
  • MBP column buffer 10 mM Tris-HCl, pH 8.4, 1 mM EDTA, 0.5 M NaCl.
  • the resin was pre-equilibrated with at least 3 column volumes of MBP column buffer containing 0.25% Tween 20. Cleared lysate as prepared above was diluted 1 part lysate to
  • the pMAL-p vector also was engineered such that a termination codon was incorporated between the Eco RI and Xba I sites. During this process, the original Eco RI site in the vector was destroyed and replaced at a position downstream from a second Factor Xa cleavage site. The second Factor Xa site was incorporated to facilitate subsequent cleavage of the decorin fusion protein from the MBP carrier.
  • the construction involved annealing complimentary oligos (OT-98 and OT-99; sequences in Table 3) and ligating into pMAL-p at the Eco RI and Xba I sites, Ausubel, et al., supra, and Maniatis, et al., supra.
  • the ligation (PT-71) was transformed into E. coli DH5 ⁇ cells, mini-preps were made from colorless colonies and the clones were sequenced for insert. Expression of the protein followed the same procedure as the MBP-Decorin fragment fusion proteins above. The results are indicated in Table 2 under "MW.”
  • Tables 4-15 below provide the nucleotide and corresponding amino acid sequences of the decorin fragment fusion proteins prepared as described above. Each table also identifies the Eco RI and Xba I ligation sites.
  • Immulon wells were coated with 0.5 ⁇ g/ml recombinant decorin at 50 ⁇ l/well. The wells were placed in a 37°C incubator overnight and thereafter washed 3 times with 200 ⁇ l PBS (0.15 M NaCl) per well to remove unbound decorin. TGF- ⁇ labeled with 125 I (400 pM, New England Nuclear, Bolton-Hunter Labeled) was pre-incubated with or without competitors in 200 ⁇ l PBS/0.05% Tween-20 for 1 hour and 45 minutes at room temperature. Competitors included recombinant human decorin preparations (DC-13 and DC-18v) , decorin fragments, and MBP as a negative control.
  • DC-13 and DC-18v are different preparations of recombinant human decorin; PT-71 or MBP (maltose-binding protein) is a negative control; PT-65 is MBP-whole decorin; PT-72 is MBP- decorin N-terminus; PT-73 is PT-72 + 2 LRR; PT-84 and PT-85 are cysteine to serine mutant of PT-72; PT-86 is decorin C terminus; PT-87 is cysteine to serine mutant of PT-86.
  • MBP maltose-binding protein
  • recombinant human decorin and MBP-decorin N-terminus inhibited 125 I-TGF-3 binding to L-M(tk-) cells.
  • An anti-TGF- ⁇ l antibody also inhibited TGF- ⁇ binding to these cells.
  • Cysteine to serine mutants of PT-72 did not inhibit 125 I-TGF-3 binding to L-M(tk-) cells.
  • Peptide H 31 - S 37 corresponds to the same decorin sequence between His-31 and Cys-37 except the Cysteine at position
  • Peptide P 25 - Q 36 corresponds to the sequence reported in Krusius and Ruoslahti, supra, from position Pro-25 through Gln-36, except the native Cysteine residues at positions 28 and 30 are each replaced with a serine.
  • Peptide H 31 - L 42 also corresponds to decorin between His-31 and Leu-42 except the cysteine at position 37 is replaced with a serine.
  • Peptide nP 25 -Q 36 corresponds exactly with decorin from position Pro-25 through Gln-36.
  • the activity of the peptides was evaluated using the L-M(tk-) TGF ⁇ l binding inhibition assay described in Example VII, except various concentrations of peptide were incubated with the cells and TGF ⁇ l instead of decorin and recombinant decorin fragments.
  • the negative control was a synthetic peptide corresponding to the first 15 amino acids of decorin, which has the sequence DEASGIGPEVPDDRD.
  • Figure 12 provides the binding data for peptides -"25 ⁇ Q3 ⁇ r H3 1 ⁇ S 37f n ⁇ ⁇ H 31 - L 42 and the control peptide. All three test peptides inhibited binding of TGF ⁇ l to L- M(tk-) cells. Peptide nP 25 - Q 36 , in which the native Cys residues remain, also demonstrated inhibitory activity, albeit to a lesser extent. Table 16 lists the test peptides in the order of decreasing inhibitory activity, i.e., peptide H 31 -S 37 was found to show the highest inhibitory activity.
  • N-terminal decorin peptide fragments synthesized and tested for their ability to inhibit TGF- ⁇ 1 binding to immobilized decorin as described above.
  • the N-terminal peptide fragments are listed in Table 17.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

L'invention décrit un procédé servant à inhiber l'activité d'un facteur de régulation cellulaire et comprenant la mise en contact dudit facteur avec un polypeptide purifié comportant un domaine de fixation de facteur régulateur cellulaire d'une protéine. La protéine est caractérisée par une répétition riche en leucine d'envrion 24 acides aminés. Dans un mode de réalisation spécifique, l'invention se rapporte à la capacité de fixation à TGFβ de la décorine, protéine de 40 000 daltons portant habituellement une chaîne de glycosaminglycane et, de façon plus spécifique, à des fragements actifs de décorine ou à ses équivalents fonctionnels. L'invention décrit également un facteur de régulation cellulaire dénommé MRF. Elle décrit également des procédés d'identification, de détection et de purification de facteur de régulation cellulaire, ainsi que des protéines se fixant audit facteur et en affectant l'activité.
EP93909477A 1992-04-03 1993-04-02 Fragments de decorine et procede d'inhibition de facteurs de regulation cellulaire Withdrawn EP0636175A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86565292A 1992-04-03 1992-04-03
US865652 1992-04-03
PCT/US1993/003171 WO1993020202A1 (fr) 1992-04-03 1993-04-02 Fragments de decorine et procede d'inhibition de facteurs de regulation cellulaire

Publications (1)

Publication Number Publication Date
EP0636175A1 true EP0636175A1 (fr) 1995-02-01

Family

ID=25345963

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93909477A Withdrawn EP0636175A1 (fr) 1992-04-03 1993-04-02 Fragments de decorine et procede d'inhibition de facteurs de regulation cellulaire

Country Status (7)

Country Link
EP (1) EP0636175A1 (fr)
JP (1) JPH07508403A (fr)
AU (1) AU679178B2 (fr)
CA (1) CA2132859A1 (fr)
FI (1) FI944575A (fr)
NO (1) NO943654L (fr)
WO (1) WO1993020202A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157388C (fr) * 1993-03-01 1998-12-15 Daniel P. Witt Composes analogues pour interactions specifiques avec une proteine d'oligosaccharide et utilisation de ceux-ci
US5567807A (en) * 1994-07-08 1996-10-22 La Jolla Cancer Research Foundation Processes for the purification of human recombinant decorin and the detection of guanidinium ions
WO2005116066A1 (fr) * 2004-05-31 2005-12-08 National University Of Singapore Peptides derives de sequences nucleotidiques repetees riches en decorine leucine et leurs utilisations
DK1806359T3 (da) * 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
ES2283212B1 (es) * 2006-03-31 2008-08-16 Lipotec S.A. Peptidos sinteticos utiles en el tratamiento de la piel y su uso en composiciones cosmeticas o dermofarmaceuticas.
HU0700024D0 (en) * 2007-01-11 2007-03-28 Mta Szegedi Biolog Koezpont Use of enhancers in biglycan activuty in the preparation of pharmaceutical compositions having utility in cardiac diseases
EP2538222B1 (fr) * 2007-11-05 2021-08-25 Nordic Bioscience A/S Marqueurs biochimiques pour évaluation de risque CVD
US20120238727A1 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010727A1 (fr) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibiteurs de facteurs regulateurs cellulaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9320202A1 *

Also Published As

Publication number Publication date
WO1993020202A1 (fr) 1993-10-14
CA2132859A1 (fr) 1993-10-14
AU679178B2 (en) 1997-06-26
NO943654L (no) 1994-12-05
FI944575A0 (fi) 1994-09-30
FI944575A (fi) 1994-11-29
JPH07508403A (ja) 1995-09-21
AU4025793A (en) 1993-11-08
NO943654D0 (no) 1994-09-30

Similar Documents

Publication Publication Date Title
US5705609A (en) Decorin fragments inhibiting cell regulatory factors
US5654270A (en) Use of fibromodulin to prevent or reduce dermal scarring
US5583103A (en) Inhibition of transforming growth factor beta activity
US7276344B2 (en) Methods for using the osteoclastogenesis inhibitory factor (OCIF) protein
AU673506B2 (en) Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
US6919434B1 (en) Monoclonal antibodies that bind OCIF
KR100687388B1 (ko) 인터루킨-18 결합 단백질, 이들의 제조방법 및 용도
WO1991010727A1 (fr) Inhibiteurs de facteurs regulateurs cellulaires
IE870535L (en) Human endothelial cell growth factor
JP2001157593A (ja) 哺乳動物ケモカインｃｃｆ１８およびレセプターｃｃｋｒ３
WO1996031526A1 (fr) Agents antiobesite
WO1995010610A1 (fr) POLYPEPTIDES DE BETAGLYCANE DOTES D'UNE ACTIVITE DE FIXATION AU FACTEUR DE CROISSANCE TRANSFORMANT DE TYPE BETA TGF-$g(b)
WO1995010610A9 (fr) POLYPEPTIDES DE BETAGLYCANE DOTES D'UNE ACTIVITE DE FIXATION AU FACTEUR DE CROISSANCE TRANSFORMANT DE TYPE BETA TGF-$g(b)
EP0636175A1 (fr) Fragments de decorine et procede d'inhibition de facteurs de regulation cellulaire
US6458932B1 (en) Interferon-α/β binding protein, its preparation and use
AU673810B2 (en) Secreted Mac-2-binding glycoprotein
US6509314B1 (en) Methods of preventing or reducing scarring with decorin or biglycan
WO1997042321A9 (fr) Proteine transporteuse d'osteoclastes
WO1997042321A1 (fr) Proteine transporteuse d'osteoclastes
EP1105477A1 (fr) Dcr5, proteine de fixation de proteines morphogenetiques osseuses, et ses applications
IL108584A (en) Cloning of the interferon-binding protein ALPHA / BETA
WO1991003251A1 (fr) Compositions du ligand cr2 et procede de modulation des fonctions de cellules immunitaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19960528

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991116